Jean Marie Arduino
YOU?
Author Swipe
View article: Lack of Knowledge and Understanding of Undetectable Equals Untransmittable (U = U) Among People Living with HIV in the United States: Results from a Cross-Sectional Survey
Lack of Knowledge and Understanding of Undetectable Equals Untransmittable (U = U) Among People Living with HIV in the United States: Results from a Cross-Sectional Survey Open
Background Launched in the United States (US) in 2016, the ‘undetectable equals untransmittable’ (U = U) message has revolutionized human immunodeficiency virus (HIV) management by affirming that individuals on antiretroviral therapy (ART)…
View article: Moving Beyond Viral Suppression: Poor Patient–Provider Communication and Its Impact on Healthcare Outcomes Among People Living With HIV in the United States
Moving Beyond Viral Suppression: Poor Patient–Provider Communication and Its Impact on Healthcare Outcomes Among People Living With HIV in the United States Open
Background While advancement in treatment have turned HIV into a manageable chronic condition achieving viral suppression, it has become imperative to focus on overall health and improving health-related quality of life of people living wi…
View article: P-540. Undesired Weight Gain and Associated Healthcare Outcomes Among People Living with HIV on Antiretroviral Therapy
P-540. Undesired Weight Gain and Associated Healthcare Outcomes Among People Living with HIV on Antiretroviral Therapy Open
Background Studies indicate that people living with HIV (PLHIV) experience weight gain associated with certain classes of antiretroviral treatment (ART). Managing overall health beyond viral suppression, including weight gain, is essential…
View article: Antiretroviral Treatment Gaps and Adherence Among People with HIV in the U.S. Medicare Program
Antiretroviral Treatment Gaps and Adherence Among People with HIV in the U.S. Medicare Program Open
View article: 2487. Low Rate of Virologic Failure in Antiretroviral Experienced Patients Prescribed Once Daily Raltegravir
2487. Low Rate of Virologic Failure in Antiretroviral Experienced Patients Prescribed Once Daily Raltegravir Open
Background Raltegravir has been used to treat HIV infection for over a decade. In 2017, a 1200 mg, once-daily, formulation of raltegravir (RALQD) was approved. We sought to characterize the utilization and effectiveness of RALQD in ART-exp…
View article: Prevalence, incidence, and risk factors for hepatitis C virus infection in hemodialysis patients
Prevalence, incidence, and risk factors for hepatitis C virus infection in hemodialysis patients Open
View article: Patient-reported outcomes in individuals with hepatitis C virus infection treated with elbasvir/grazoprevir
Patient-reported outcomes in individuals with hepatitis C virus infection treated with elbasvir/grazoprevir Open
NCT02358044.
View article: 555. Characteristics of HIV+ Patients Prescribed Raltegravir QD in the United States
555. Characteristics of HIV+ Patients Prescribed Raltegravir QD in the United States Open
BACKGROUND: Raltegravir (RAL) 400 mg twice-daily (RAL BID) has been an integral part of antiretroviral therapy (ART) in both ART naïve and experienced HIV-1 infected patients for the last decade. In 2017, RAL 1,200 mg (2 × 600 mg), a once-…
View article: Kidney Function Decline in Patients with CKD and Untreated Hepatitis C Infection
Kidney Function Decline in Patients with CKD and Untreated Hepatitis C Infection Open
Background and objectives Studies evaluating the role of hepatitis C viral (HCV) infection on the progression of CKD are few and conflicting. Therefore, we evaluated the association of untreated HCV on kidney function decline in patients w…
View article: Effectiveness, treatment completion and safety of sofosbuvir/ledipasvir and paritaprevir/ritonavir/ombitasvir + dasabuvir in patients with chronic kidney disease: an ERCHIVES study
Effectiveness, treatment completion and safety of sofosbuvir/ledipasvir and paritaprevir/ritonavir/ombitasvir + dasabuvir in patients with chronic kidney disease: an ERCHIVES study Open
Summary Background Chronic kidney disease ( CKD ) was a relative contraindication to hepatitis C virus ( HCV ) treatment in the interferon/ribavirin era. Aim To determine the efficacy, tolerability and safety of sofosbuvir/ledipasvir ( SOF…
View article: Supplementary Material for: Impact of Renal Disease on Patients with Hepatitis C: A Retrospective Analysis of Disease Burden, Clinical Outcomes, and Health Care Utilization and Cost
Supplementary Material for: Impact of Renal Disease on Patients with Hepatitis C: A Retrospective Analysis of Disease Burden, Clinical Outcomes, and Health Care Utilization and Cost Open
Background/Aims: Few studies explore the magnitude of the disease burden and health care utilization imposed by renal disease among patients with hepatitis C virus (HCV). We aimed to describe the characteristics, outcomes, an…
View article: Supplementary Material for: Impact of Renal Disease on Patients with Hepatitis C: A Retrospective Analysis of Disease Burden, Clinical Outcomes, and Health Care Utilization and Cost
Supplementary Material for: Impact of Renal Disease on Patients with Hepatitis C: A Retrospective Analysis of Disease Burden, Clinical Outcomes, and Health Care Utilization and Cost Open
Background/Aims: Few studies explore the magnitude of the disease burden and health care utilization imposed by renal disease among patients with hepatitis C virus (HCV). We aimed to describe the characteristics, outcomes, an…
View article: HCV Treatment Initiation in Patients with Chronic Kidney Disease: Results from ERCHIVES
HCV Treatment Initiation in Patients with Chronic Kidney Disease: Results from ERCHIVES Open
Newer directing antiviral agents against HCV (DAAs) are safe and efficacious in persons with chronic kidney disease (CKD). Whether availability of these newer DAAs has resulted in more persons with CKD initiating HCV treatment remains unkn…
View article: Effectiveness and Safety of Sofosbuvir/Ledipasvir and Paritaprevir/ritonavir/Ombitasvir + Dasabuvir in Patients with Chronic Kidney Diseases: Results from ERCHIVES
Effectiveness and Safety of Sofosbuvir/Ledipasvir and Paritaprevir/ritonavir/Ombitasvir + Dasabuvir in Patients with Chronic Kidney Diseases: Results from ERCHIVES Open
View article: The Impact of Hepatitis C Virus on Kidney-Related Outcomes Among Patients with Chronic Kidney Disease
The Impact of Hepatitis C Virus on Kidney-Related Outcomes Among Patients with Chronic Kidney Disease Open
View article: The Impact of Chronic Kidney Disease on Hepatic and Extra Hepatic Outcomes Among Patients With Hepatitis C Infection
The Impact of Chronic Kidney Disease on Hepatic and Extra Hepatic Outcomes Among Patients With Hepatitis C Infection Open
View article: The Impact of Untreated Hepatitis C Infection on Progression of Renal Decline Among Patients With Chronic Kidney Disease
The Impact of Untreated Hepatitis C Infection on Progression of Renal Decline Among Patients With Chronic Kidney Disease Open
Background.Whether untreated hepatitis C virus infection (HCV) accelerates the progression of renal decline and development of end-stage renal disease (ESRD) among patients with chronic kidney disease (CKD) is poorly understood.Methods.Pat…
View article: FP358HEPATITIS C VIRUS (HCV) INFECTION AND CHANGE IN RENAL FUNCTION
FP358HEPATITIS C VIRUS (HCV) INFECTION AND CHANGE IN RENAL FUNCTION Open
View article: Staphylococcus aureus infections following knee and hip prosthesis insertion procedures
Staphylococcus aureus infections following knee and hip prosthesis insertion procedures Open
Post-operative invasive S. aureus infections were rare, but difficult-to-treat methicillin-resistant infections were relatively common. Optimizing preventative efforts may greatly reduce the healthcare burden associated with S. a…